Baseline ECOG Performance Status 0 Versus 1 as a Modifier of Treatment Benefit from Adding an Immune Checkpoint Inhibitor to Chemotherapy: A Systematic Review and Meta-Analysis.
BACKGROUND Immune checkpoint inhibitors (ICIs) added to chemotherapy are established in solid tumors, but most trials enroll patients with ECOG performance status (PS) 0-1 patients. Whether baseline PS modifies the relative benefit of adding an ICI has not been formally tested using a within-trial interaction analysis....